ATE480257T1 - Kombinationsvakzine mit niedriger dosis eines hib-konjugats - Google Patents

Kombinationsvakzine mit niedriger dosis eines hib-konjugats

Info

Publication number
ATE480257T1
ATE480257T1 AT05727218T AT05727218T ATE480257T1 AT E480257 T1 ATE480257 T1 AT E480257T1 AT 05727218 T AT05727218 T AT 05727218T AT 05727218 T AT05727218 T AT 05727218T AT E480257 T1 ATE480257 T1 AT E480257T1
Authority
AT
Austria
Prior art keywords
hib
low dose
combination vaccine
dose combination
hib conjugate
Prior art date
Application number
AT05727218T
Other languages
German (de)
English (en)
Inventor
Mario Contorni
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE480257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE480257T1 publication Critical patent/ATE480257T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT05727218T 2004-03-15 2005-03-14 Kombinationsvakzine mit niedriger dosis eines hib-konjugats ATE480257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines
PCT/IB2005/000927 WO2005089794A2 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate

Publications (1)

Publication Number Publication Date
ATE480257T1 true ATE480257T1 (de) 2010-09-15

Family

ID=32117706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05727218T ATE480257T1 (de) 2004-03-15 2005-03-14 Kombinationsvakzine mit niedriger dosis eines hib-konjugats

Country Status (13)

Country Link
US (2) US20090208526A1 (enExample)
EP (1) EP1725258B1 (enExample)
JP (2) JP4954056B2 (enExample)
CN (2) CN102028944B (enExample)
AT (1) ATE480257T1 (enExample)
BR (1) BRPI0508813B8 (enExample)
CA (1) CA2559996C (enExample)
DE (1) DE602005023422D1 (enExample)
DK (1) DK1725258T3 (enExample)
GB (1) GB0405787D0 (enExample)
RU (1) RU2435609C2 (enExample)
SG (1) SG151253A1 (enExample)
WO (1) WO2005089794A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1296715T2 (sl) * 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
WO2009133408A2 (en) * 2008-05-01 2009-11-05 Arecor Limited Protein formulation
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
CN102655879B (zh) * 2009-12-16 2016-03-09 印度血清研究所 疫苗组合物
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
CN103796683A (zh) 2011-04-21 2014-05-14 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
AU2013338153B2 (en) * 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
MX2020000441A (es) 2017-07-18 2020-08-17 Serum Inst Of India Pvt Ltd Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma.
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN118903397A (zh) * 2024-10-12 2024-11-08 成都迈科康生物科技有限公司 GloboH六糖、linker化合物、蛋白偶联物及免疫原性组合物在治疗或抑制上皮性肿瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
EP1082965B1 (en) * 1995-06-23 2009-06-10 GlaxoSmithKline Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
SI1296715T2 (sl) 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva

Also Published As

Publication number Publication date
JP2008150397A (ja) 2008-07-03
CN102028944B (zh) 2013-12-04
CA2559996A1 (en) 2005-09-29
WO2005089794A2 (en) 2005-09-29
US20120107346A1 (en) 2012-05-03
CN102028944A (zh) 2011-04-27
CA2559996C (en) 2014-08-05
GB0405787D0 (en) 2004-04-21
BRPI0508813B1 (pt) 2019-05-21
US9259460B2 (en) 2016-02-16
RU2006136212A (ru) 2008-04-27
RU2435609C2 (ru) 2011-12-10
CN1968711B (zh) 2011-01-05
EP1725258B1 (en) 2010-09-08
WO2005089794A3 (en) 2006-03-09
EP1725258A2 (en) 2006-11-29
SG151253A1 (en) 2009-04-30
BRPI0508813A (pt) 2007-08-07
JP4954056B2 (ja) 2012-06-13
BRPI0508813B8 (pt) 2021-05-25
CN1968711A (zh) 2007-05-23
US20090208526A1 (en) 2009-08-20
DE602005023422D1 (de) 2010-10-21
JP2007529503A (ja) 2007-10-25
DK1725258T3 (da) 2010-11-01

Similar Documents

Publication Publication Date Title
ATE480257T1 (de) Kombinationsvakzine mit niedriger dosis eines hib-konjugats
UY26801A1 (es) Composición de vacuna
RU2008112289A (ru) Множественная вакцинация, включающая менингококки серогруппы с
ES2388690T3 (es) Composición de vacuna multivalente
RU2009149359A (ru) Состав вакцин против менингита
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
ATE463261T1 (de) Meningokokken-konjugat-impfung
NO20015073L (no) Vaksiner
NO20082647L (no) Vaksine
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
JP2015531389A5 (enExample)
CO4910171A1 (es) Vacunas comprendiendo bajas dosis de antigenos de difteria, tetano y tos ferina acelular ( dtpa )
JP2009514840A5 (enExample)
WO2005007804A3 (en) Anthrax conjugate vaccine and antibodies
ES2365557T5 (es) Vacunas de combinación de Poliovirus inactivado
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties